

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701-3271 WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512 TELEPHONE: (512

(512) 536-3184 (512) 474-5201

FACSIMILE: (512) 536-4598

November 17, 2003

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD demmissioner for Patents, P.O. Box 1450, Alexandia, VA 22313-1450, on the date below:

November 17, 2003

Date

Steven L. Highlander

MS DD

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

RE: U.S. Patent Application No. 10/655,562 entitled "PHAGE-DISPLAY PEPTIDES AS NOVEL

ANTIMICROBIAL AGENTS AGAINST HAEMOPHILUS INFLUENZAE" - Sharon L. Bishop-

Hurley et al.

Our reference: UVMO:022US Client reference: 02UMC041

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1 and C1.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UVMO:022US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

(espectfully submitted,

Steven L. Highlander Reg. No. 37,642

SLH/kmv Encl.: as noted

25356921.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of:
Sharon L. Bishop-Hurley *et al*.

Serial No.: 10/655,562

Filed: September 4, 2003

For: PHAGE-DISPLAY PEPTIDES AS NOVEL ANTIMICROBIAL AGENTS AGAINST HAEMOPHILUS INFLUENZAE

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UVMO:022US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS DD, formissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

November 17, 2003

Date

Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

MS DD

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the

Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit

Account No.: 50-1212/UVMO:022US.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

Steven L. Highlander

Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

November 17, 2003

Fo	rm PTO-1449 (modified)		Atty. Docket No. UVMO:022US	Serial No. 10/655,562	
	st of Patents and Publications for INFORMATION DISCLOSURE S		Applicant Sharon L. Bishop-Hurle	ey et al.	
MON 5 0 5003	(Use several sheets if necessary)		Filing Date: September 4, 2003	Group: Unknown	
TO MADERALITY	U.S. Patent Documents See Page 1		Patent Documents See Page 1	Other Art See Page 1	

U.S. Patent Docum	ient	S
-------------------	------	---

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	6,020,154	02/01/00	Hansen et al.	435	69.1	04/20/95

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Boyle-Vavra et al., "Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates," Antimicrob. Agents Chemother., 44(2):272-277, 2000.

25346874.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.